Safety and Efficacy of a Bolus Injection of Landiolol Hydrochloride as a Premedication for Multidetector-Row Computed Tomography Coronary Angiography

Kazuhiro Osawa, MD; Toru Miyoshi, MD; Shuhei Sato, MD; Noriaki Akagi; Yusuke Morimitsu; Kazufumi Nakamura, MD; Kunihisa Kohn, MD; Kengo Kusano, MD; Susumu Kanazawa, MD; Hiroshi Ito, MD

**Background:** We evaluated the safety and efficacy of a bolus injection of landiolol hydrochloride, an ultrashort-acting β1-selective antagonist, as an additional treatment after premedication with an oral β-blocker to reduce heart rate prior to multidetector-row computed tomography (MDCT) coronary angiography (CAG).

**Methods and Results:** A total of 458 patients who underwent MDCT CAG were retrospectively enrolled. Image quality and hemodynamic parameters were compared in patients before and after approval of landiolol hydrochloride. If heart rate reduction was insufficient after premedication with an oral β-blocker, a bolus injection of landiolol hydrochloride (n=66) or other drugs (n=30) was used. The percentage of evaluable images per segment in patients after approval of landiolol (99.3%) was greater than that in patients before approval of landiolol (97.4%, P<0.01). Heart rates before scanning in patients receiving landiolol hydrochloride were similar to those receiving other drugs. Heart rate was significantly reduced approximately 5 min after injection of landiolol hydrochloride and increased shortly. No decrease in systolic blood pressure or other adverse effects was observed.

**Conclusions:** Bolus injection of landiolol hydrochloride sufficiently reduced heart rate without significantly reducing systolic blood pressure and produced a high percentage of evaluable images, suggesting that bolus injection of landiolol hydrochloride as an additional pretreatment is feasible in MDCT CAG. (**Circ J** 2013; 77: 146–152)

**Key Words:** β-blocker; Coronary angiography; Landiolol; Multidetector-row computed tomography
Patients who visited Okayama University Hospital or Tsuyama Central Hospital between January 2011 and February 2012 for 64-slice MDCT examination because of suspected coronary artery disease. Patients with any heart rhythm other than sinus rhythm, with any contraindication for β-blockers, or an inability to hold their breath on command were excluded. Patients with previous myocardial infarction or those with coronary stents were included, but patients who had undergone coronary artery bypass graft surgery were excluded. This study was approved by the institutional ethics committee on human research and written informed consent was given by all patients before the study.

Patient Preparation
Landiolol hydrochloride (Corebeta, Ono Pharmaceutical Co, Osaka, Japan) was approved in November 2011 for use at Okayama University Hospital and in December 2011 for use at Tsuyama Central Hospital. The study participants were divided into 2 groups: those examined before landiolol was approved (n=229) and those examined after landiolol was approved (n=229). A diagram of the study protocol is shown in Figure 1. All patients arrived at the hospital 1 h before the scheduled scanning time, and those who showed a persistently high HR of ≥60 beats/min received oral metoprolol (20–40 mg). If the HR was not sufficiently lowered (<60 beats/min) before the scheduled scanning time, patients who were treated prior to landiolol approval received additional oral metoprolol (20 mg; n=22) and/or 2 mg intravenous propranolol (n=8) and/or 5 mg intravenous verapamil (n=9) as additional pretreatments. After approval of landiolol, patients received a bolus injection of landiolol hydrochloride at a dose of 0.125 mg/kg as an additional pretreatment if the HR was not sufficiently lowered. Landiolol hydrochloride was injected intravenously 4–7 min before starting MDCT. Additional premedication was given to 30 patients before approval of landiolol and 66 patients after approval of landiolol.

Data Acquisition
The 64-slice CT scans were obtained using a DCT scanner (Okayama University Hospital: SOMATOM Definition Flash, Siemens Medical Solutions, Germany; Tsuyama Central Hospital: Lightspeed VCT, GE Healthcare, USA). SOMATOM Definition Flash parameters were as follows: detector collimation 64×0.6 mm, equaling a slice acquisition of 128×0.6 mm using the flying focal spot technique; table pitch adapted to HR (0.17–0.38); rotation time 275 ms; tube current time product 360 mA; and tube voltage 120 kVp. Lightspeed VCT parameters were: rotation time 350 ms; pitch 0.516 mm per gantry rotation; helical acquisition mode; detector configuration 64 rows with 0.625-mm-thick sections; and tube voltage 120 kVp. At Okayama University Hospital, a test bolus CT acquisition was performed at the level of the ascending aorta following administration of 10 ml contrast medium followed by 20 ml saline, with low-dose images obtained every 1 s. The delay before the formal scan was calculated as the time to peak enhancement in the ascending aorta plus 3 s to ensure enhancement of the distal segments of the coronary arteries. For the final scan, contrast agents (Omnipaque 350, Daiichi
Sankyo, Japan) were injected over 10 s, followed by a second bolus of 80% of the amount of contrast medium diluted 50%, and then a chaser bolus of saline. All injections were done at the same flow rate, calculated as body weight ×0.07 ml/s. At Tsuyama Central Hospital, the test bolus tracking method was performed. The amount of contrast material (Iopamiron 370, Bayer, Germany) was calculated as 330 mgI/kg. The flow time was fixed at 15 s, and the flow rate was calculated accordingly. A test bolus was performed with 5 ml of contrast material followed by 20 ml of saline at the same flow rate. The main injection was performed continuously at the same flow rate followed by 20 ml of saline.

Axial slices were optimally reconstructed within the mid-to end-diastolic phase in each patient using retrospective ECG gating and commercially available cardiac reconstruction software (AZE Inc, Tokyo, Japan). Three postprocessing techniques were applied to assess the coronary arteries: (1) maximum intensity projection, (2) curved multiplanar reconstruction, and (3) volume rendering. One senior cardiologist and 2 senior CT technicians performed the analysis, and evaluation was made on a per-segment basis. Sixteen segments were identified based on the established American Heart Association segment model and consisted of the right coronary artery and distal branches (5 segments), left main trunk (1 segment), left main anterior descending artery and branches (5 segments), and circumflex artery and branches (5 segments). Segments that were absent or too small, or that contained heavy calcification or a stent, were excluded. Each segment was classified as evaluable or not evaluable as described.

Non-evaluable images were defined as those with no vessel wall definition owing to marked motion artifacts, significant structural discontinuity, or high image noise-related blurring that precluded the acquisition of diagnostic information. Segments that could be evaluated included those with excellent, good, or fair quality. Images with excellent quality were defined as those with no motion artifacts, noise-related blurring, or structural discontinuity. Images with good quality were defined as those with only minor motion artifacts or noise-related blurring and no structural discontinuity. Images with fair quality were those with some motion artifacts, noise-related blurring, or minimal structural discontinuity. Image quality was evaluated by 2 experienced observers who had no knowledge of pretreatments for reducing HR for MDCT CAG. The interobserver coefficient of variation analyzed from 20 randomly selected samples was <5%.

Evaluation of Adverse Effects of Additional Treatment

Hemodynamic parameters (systolic blood pressure (BP), diastolic BP, and HR) were evaluated for all patients upon entry into the CT room and immediately before and after scanning. For patients treated with landiolol hydrochloride, additional measurements were taken before the bolus injection. Potential adverse effects of landiolol hydrochloride (hypotension, floating sensation, dizziness, serious bradycardia, and cardiogenic shock) were also assessed by nurses.

Statistical Analysis

Continuous variables are presented as the mean±SD, and differences between the 2 groups were evaluated using an unpaired t-test. Categorical variables are presented as frequencies, and intergroup comparisons were analyzed using the χ² test. One-way ANOVA was performed followed by a post-hoc Bonferroni test to examine differences in the time course of hemodynamic changes. A P value <0.05 was considered statistically significant. Statistical analysis was performed using SPSS 17.0 for Windows (SPSS Inc, Chicago, IL, USA).

Results

Clinical characteristics of the 458 enrolled patients are summarized in Table 1. Our study included 244 men (53%) with a mean age of 66 years. Patients seen before approval of landiolol had a greater prevalence of dyslipidemia, but the prevalence of hypertension and of diabetes mellitus was com-

| Table 1. Characteristics of Patients’ Undergoing MDCT CAG Before and After Approval of Landiolol Hydrochloride in Japan |
|-----------------|-----------------|-----------------|-----------------|
|                | Before approval of landiolol | After approval of landiolol |
| Age (years)    | All (n=229)       | Patients receiving additional pretreatments (n=30) | All (n=229)       | Patients receiving landiolol (n=66) |
| Men            | 67±12            | 67±12           | 66±14           | 66±13             |
| BMI (kg/m²)    | 117 (51%)        | 15 (50%)        | 127 (56%)       | 32 (49%)          |
| Hypertension   | 22.9±3.8         | 22.6±3.6        | 22.9±3.8        | 22.3±3.0          |
| Hypertension   | 22.6±3.6         |                  | 22.3±3.0        |                  |
| Diabetes mellitus | 66 (29%)        | 11 (37%)        | 58 (25%)        | 21 (32%)          |
| Angina pectoris | 52 (23%)         | 6 (20%)         | 41 (18%)        | 12 (18%)          |
| Prior MI       | 10 (4%)          | 1 (3%)          | 7 (3%)          | 2 (3%)            |
| History of stent implantation | 15 (7%)       | 1 (3%)          | 9 (4%)          | 1 (2%)            |
| Medications    | β-blocker        | 26 (11%)        | 2 (7%)          | 21 (9%)          |
|                | CCB              | 66 (29%)        | 11 (37%)        | 79 (35%)          |
|                | ACEI/ARB         | 93 (41%)†       |                | 27 (41%)†         |

Values represent mean±SD or number (%). *P<0.05 vs. all patients before approval of landiolol; †P<0.05 vs. all patients after approval of landiolol.

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CAG, coronary angiography; CCB, calcium-channel blocker; MDCT, multidetector-row computed tomography; MI, myocardial infarction.
Landiolol and MDCT CAG

Table 2. Quality of Images Obtained Per Segment, Per Artery, and Per Patient in Patients’ Undergoing MDCT CAG Before and After Approval of Landiolol Hydrochloride in Japan

|                          | Before approval of landiolol | After approval of landiolol | P value |
|--------------------------|------------------------------|----------------------------|---------|
| In all patients          |                              |                            |         |
| n                        | 229                          | 229                        |         |
| Per segment              | 3,237/3,310 (97.8%)          | 3,333/3,383 (98.5%)        | 0.03    |
| Per artery               |                              |                            |         |
| LMT                      | 229/229 (100%)               | 229/229 (100%)             | 1       |
| LAD                      | 201/229 (87.8%)              | 217/229 (94.8%)            | <0.01   |
| LCX                      | 213/229 (93.0%)              | 217/229 (94.8%)            | 0.44    |
| RCA                      | 208/229 (90.8%)              | 217/229 (94.8%)            | 0.10    |
| Per patient              | 182/229 (79.4%)              | 203/229 (88.6%)            | <0.01   |
| In patients who received additional pretreatment |                              |                            |         |
| n                        | 30                           | 66                         |         |
| Per segment              | 418/429 (97.4%)              | 985/992 (99.3%)            | <0.01   |

Table 3. Hemodynamic Parameters in Patients Who Received Additional Pretreatments Among Patients’ Undergoing MDCT CAG Before and After Approval of Landiolol Hydrochloride in Japan

|                          | Before approval of landiolol (n=30) | After approval of landiolol (n=66) | P value |
|--------------------------|------------------------------------|-----------------------------------|---------|
| At outpatient clinic     |                                    |                                   |         |
| SBP (mmHg)               | 144±16                             | 135±19                            | 0.05    |
| DBP (mmHg)               | 84±12                              | 81±13                             | 0.33    |
| HR (beats/min)           | 89±12                              | 78±10                             | <0.01   |
| Before the additional pretreatment |                          |                                   |         |
| SBP (mmHg)               | 129±16                             | 122±19                            | 0.09    |
| DBP (mmHg)               | 78±12                              | 72±13                             | 0.02    |
| HR (beats/min)           | 77±12                              | 76±10                             | 0.70    |
| At the time of scanning  |                                    |                                   |         |
| SBP (mmHg)               | 137±19                             | 120±18                            | <0.01   |
| DBP (mmHg)               | 77±14                              | 68±12                             | <0.01   |
| HR (beats/min)           | 68±9                               | 67±10                             | 0.35    |
| After scanning           |                                    |                                   |         |
| SBP (mmHg)               | 136±29                             | 127±19                            | 0.02    |
| DBP (mmHg)               | 77±16                              | 70±13                             | 0.03    |
| HR (beats/min)           | 66±10                              | 70±10                             | 0.07    |

DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure. Other abbreviations as in Table 1.
significantly higher after approval of landiolol than before approval of landiolol (98.5% vs. 97.8%, respectively, $P=0.03$). When image qualities were analyzed according to the left main trunk, left anterior descending artery, left circumflex artery, and right coronary artery, the percentage of evaluable images in the left anterior descending artery was significantly higher after approval of landiolol than before approval of landiolol (94.8% vs. 87.8%, respectively, $P<0.01$). For patient-based analysis, 203 patients after approval of landiolol and 182 patients before approval of landiolol showed no motion artifacts (88.6% vs. 79.4%, respectively, $P<0.01$).

In patients who received additional pretreatment, the percentage of evaluable segments was significantly higher after approval of landiolol than before approval of landiolol (99.3% vs. 97.4%, respectively, $P<0.01$). When image quality was analyzed according to artery, the percentage of evaluable images in the left anterior descending artery was significantly higher after approval of landiolol than before approval of landiolol (93.9% vs. 76.7%, respectively, $P=0.01$). For patient-based analysis, the evaluable percentage was significantly higher after approval of landiolol than before approval of landiolol (100% vs. 90%, respectively, $P<0.01$). For patient-based analysis, the evaluable percentage was significantly higher after approval of landiolol than before approval of landiolol (99.3% vs. 97.4%, respectively, $P<0.01$). When image quality was analyzed according to artery, the percentage of evaluable images in the left anterior descending artery was significantly higher after approval of landiolol than before approval of landiolol (93.9% vs. 76.7%, respectively, $P=0.01$).

Hemodynamic parameters assessed immediately before scanning and after scanning are shown in Table 3. HR was significantly higher in patients receiving other drugs than in patients receiving landiolol. HRs just before and after scanning were comparable between patients receiving landiolol and those receiving other drugs. BP just before scanning was significantly lower in patients receiving landiolol than in those receiving other drugs ($P<0.01$). For patients treated with landiolol ($n=66$), Figure 2 shows the time course of BP and HR upon entry to the CT room, before the bolus injection and immediately before and after scanning. HR was significantly decreased before scanning and then significantly increased after scanning.

Figure 2. Graph showing the sequential changes in heart rate (A) and blood pressure (B) immediately after scanning of 66 patients given landiolol upon entry to the CT room. Data are expressed as mean±SD. SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate.
after scanning, but did not recover to the same level as before scanning. There were no significant decreases in systolic BP over the same time course. There were no adverse effects from landiolol hydrochloride; however, 1 patient who received 2 mg intravenous propranolol and 5 mg intravenous verapamil developed low BP for which an intravenous hypertensive agent was necessary. The amount of time from the beginning of the visit to the outpatient clinic to the end of the CT scan was significantly shorter in patients after approval of landiolol (n=229) than before approval of landiolol (n=229) (90±13 vs. 159±45 min, respectively, P<0.01).

Discussion
This study revealed that for patients who had an elevated HR after an initial metoprolol dose prior to MDCT CAG, a bolus injection of landiolol hydrochloride was safe and resulted in better image quality that with the conventional protocol without landiolol hydrochloride. This is the first study to demonstrate the clinical applicability of a bolus injection of landiolol hydrochloride as a pretreatment in combination with an oral β-blocker for MDCT CAG.

Cardiac motion artifacts are a major problem in obtaining optimal coronary vessel images during MDCT, and thus HR must be adequately controlled. 5-14 Oral β-blocking agents are widely used to reduce HR, but they are not always sufficient. 15 Landiolol has similar pharmacological properties as esmolol, but is short-acting and highly selective for β1 receptors, thus showing fewer side effects than other longer-acting β-blockers. 5,15 Recent studies have shown landiolol to be safe and effective in patients with perioperative atrial fibrillation or tachycardia, 9,11,13 in patients with severe ventricular arrhythmia or acute decompensated heart failure, 11 and for early initiation of β-blockers in patients with acute myocardial infarction. 12 In addition, Isobe et al reported the usefulness of continuous infusion of landiolol hydrochloride for MDCT CAG. 14 Although continuous infusion of landiolol hydrochloride is reported to be safe, 14 such a procedure seems complicated in an outpatient clinic. Compared with continuous injection, the bolus injection used in this study was more practical. Furthermore, this study showed that only approximately 20% of patients who were scheduled for MDCT CAG required any premedication beyond oral β-blocker treatment. Therefore, the use of landiolol hydrochloride in selected patients may have cost-benefit advantages.

Our study assessed the effect of landiolol hydrochloride on hemodynamics during MDCT CAG. Among the patients imaged before approval of landiolol, I developed severe hypotension that required treatment. The protocol using a bolus injection of landiolol hydrochloride produced only a transient reduction in HR and no significant change in systolic BP. Furthermore, the amount of time from the beginning of premedication to the end of the CT scan was strikingly shorter in patients receiving landiolol hydrochloride than in those receiving other additional drugs. Thus, landiolol hydrochloride as an additional pretreatment may be useful in MDCT CAG.

Our study also compared image quality in patients before and after approval of landiolol. Although the image quality was significantly better in patients receiving landiolol hydrochloride than in those receiving other drugs, we believe that the difference was not clinically important. The overall percentage of evaluable images in both groups was 97–99%, which is sufficient for clinical use. Recent studies have shown that the percentage of evaluable images is over 90–95% when the HR is controlled appropriately. 5,21,24 Image quality with MDCT CAG is affected not only by absolute HR, but also by variability in HR. 21 However, we could not examine the difference in HR variability during CT scanning, because no data were available for patients who received additional pretreatments without landiolol. A possible explanation for the improved image quality in patients receiving landiolol hydrochloride is that it reduced HR variability during the CT scan more effectively than other drugs such as verapamil.

Study Limitations
The first limitation of our study is that among the total 458 patients enrolled, only 96 received additional premedication, including landiolol hydrochloride. Therefore, further investigation in a larger population is needed to make solid conclusions regarding the safety of landiolol hydrochloride and image quality in individual patients. Second, in this study, a greater number of patients required additional pretreatment after approval of landiolol than before approval. Although our medical staff tried to follow the protocol, additional pretreatments were not used in some cases before approval of landiolol, especially in patients whose HRs were near 60 beats/min because of concerns about adverse effects of additional β-blocker injection, delay of another scheduled CT, and extension of the patient’s examination time. In similar situations after landiolol approval, however, more patients may have been given additional pretreatment because of fewer concerns. It is possible that these factors affected our results. Third, patients with heavily calcified lesions, stents, and bypass grafts were excluded from our analysis. Also, sublingual nitroglycerin was used in all patients. These factors may have affected image quality. However, every assessable arterial branch was included in our analyses, regardless of diameter.

Conclusions
Bolus injection of the ultrashort-acting β-blocker, landiolol hydrochloride, reduced HR to a level suitable for MDCT without causing a significant reduction in BP. Use of landiolol hydrochloride in combination with metoprolol for HR control shortened the total procedure time compared with the use of other secondary drugs, and high-quality images were obtained. Therefore, a bolus injection of landiolol hydrochloride is feasible as an additional premedication for MDCT CAG.

Acknowledgments
The authors thank Y. Koyama, T. Oka, M. Yoshikawa, J. Iwasaki, S. Sakuragi and Y. Katayama for participating in study design, and M. Yamagami, S. Kusai, S. Koumoto, M. Taira and J. Suetsoshi for their excellent technical support.

Disclosures
Conflicts of Interest: The authors declare no conflicts of interest.

References
1. Achenbach S, Giesler T, Kopfer D, Ulheimer S, Derlien H, Schulte C, et al. Detection of coronary artery stenoses by contrast-enhanced, retrospectively electrocardiographically-gated, multislice spiral computed tomography. Circulation 2001; 103: 2535–2538.
2. Matsumoto N, Nagao K, Hirayama A, Sato Y. Non-invasive assessment and clinical strategy of stable coronary artery disease by magnetic resonance imaging, multislice computed tomography and myocardial perfusion SPECT. Circ J 2010; 74: 34–40.
3. Motoyama S, Kondo T, Anno H, Sugihara A, Ito Y, Mori K, et al. Atherosclerotic plaque characterization by 0.5-mm-slice multislice computed tomographic imaging. Circ J 2007; 71: 363–366.
4. Nieman K, Cademartiri F, Lemos PA, Raaijmakers R, Pattynama PM, de Feyter PJ. Reliable noninvasive coronary angiography with fast
submillimeter multislice spiral computed tomography. Circulation 2002; 106: 2051–2054.
5. Shim SS, Kim Y, Lim SM. Improvement of image quality with beta-blocker premedication on ECG-gated 16-MDCT coronary angiography. Am J Roentgenol 2005; 184: 649–654.
6. Sugiyama A, Takahara A, Hashimoto K. Electrophysiologic, cardiohemodynamic and beta-blocking actions of a new ultra-short-acting beta-blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol. J Cardiovasc Pharmacol 1999; 34: 70–77.
7. Ikeshita K, Nishikawa K, Toriyama S, Yamashita T, Tani Y, Yamada T, et al. Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts. J Anesth 2008; 22: 361–366.
8. Sakamoto A, Kitakaze M, Takamoto S, Namiki A, Kasanuki H, Hosoda S, Landiolol, an ultra-short-acting β₁-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery. Circ J 2012; 76: 1097–1101.
9. Nakano T, Shimizu K, Kawashima O, Kamiyoshihara M, Nagashima T, Ibe T, et al. Effect of landiolol hydrochloride, an ultra-short-acting beta-1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection. J Clin Pharm Ther 2012; 37: 431–435.
10. Miwa Y, Ikeda T, Mera H, Miyakoshi M, Hoshimoto K, Yanagisawa R, et al. Effects of landiolol, an ultra-short-acting β₁-selective blocker, on electrical storm refractory to class III antiarrhythmic drugs. Circ J 2010; 74: 856–863.
11. Kobayashi S, Susa T, Tanaka T, Murakami W, Fukuta S, Okuda S, et al. Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. Circ J 2012; 76: 1646–1653.
12. Hanada K, Higuma T, Nishizaki F, Sukekawa T, Yokota T, Yamada M, et al. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β₁-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J 2012; 76: 439–445.
13. Fujii M, Bessho R, Ochi M, Shimizu K, Terajima K, Takeda S. Effect of postoperative landiolol administration for atrial fibrillation after off pump coronary artery bypass surgery. J Cardiovasc Surg (Torino) 2012; 53: 369 – 374.
14. Isobe S, Sato K, Sugiuara K, Minuma T, Kobayashi M, Menco C, et al. Feasibility of intravenous administration of landiolol hydrochloride for multislice computed tomography coronary angiography: Initial experience. Circ J 2008; 72: 1814–1820.
15. Sato Y, Matsumoto N, Kato M, Insue F, Horie T, Kusama J, et al. Noninvasive assessment of coronary artery disease by multislice spiral computed tomography using a new retrospectively ECG-gated image reconstruction technique. Circ J 2003; 67: 401–405.
16. Austen WG, Edwards JE, Frye RJ, Gensini GG, Gott VL, Griffith LS, et al. A reporting system on patients evaluated for coronary artery disease: Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51: 5–40.
17. Hoffmann MH, Shi H, Manzke R, Schmid FT, De Vries L, Grass M, et al. Noninvasive coronary angiography with 16-detector row CT: Effect of heart rate. Radiology 2005; 234: 86–97.
18. Leber AW, Knez A, Becker C, Becker A, White C, Thiolo C, et al. Non-invasive intravenous coronary angiography using electron beam tomography and multislice computed tomography. Heart 2003; 89: 633–639.
19. Shuman WP, Branch KR, May JM, Mitsumori LM, Lockhart DW, Dubinsky TJ, et al. Prospective versus retrospective ECG gating for 64-detector CT of the coronary arteries: Comparison of image quality and patient radiation dose. Radiology 2008; 248: 431–437.
20. Cademartiri F, Mollet NR, Runza G, Belgrano M, Malaguti P, Meijboom BW, et al. Diagnostic accuracy of multislice computed tomography coronary angiography is improved at low heart rates. Int J Cardiovasc Imaging 2006; 22: 101 – 105; Discussion 107–109.
21. Hoffmann MH, Shi H, Schmitz BL, Schmid FT, Lieberknecht M, Schulze R, et al. Noninvasive coronary angiography with multislice computed tomography. JAMA 2005; 293: 2471–2478.
22. Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC, Hecht HS, et al. ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010; 121: 2509–2543.
23. Shibata S, Okamoto Y, Endo S, Ono K. Direct effects of esmolol and landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts. J Pharmacol Sci 2012; 118: 255 – 265.
24. Mollet NR, Cademartiri F, Nieman K, Saia F, Lemos PA, McFadden EP, et al. Multislice spiral computed tomography coronary angiography in patients with stable angina pectoris. J Am Coll Cardiol 2004; 43: 2265–2270.
25. Leschka S, Wildermuth S, Boehm T, Desbiolles L, Husmann L, Plass A, et al. Noninvasive coronary angiography with 64-section CT: Effect of average heart rate and heart rate variability on image quality. Radiology 2006; 241: 378–385.